Risk Factors for Multidrug-resistant Invasive Pneumococcal Disease in South Africa, a Setting with High HIV Prevalence, in the Prevaccine Era from 2003 to 2008

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2012 Jul 18

PMID 22802256

Citations 13

Authors

Penny Crowther-Gibson

Cheryl Cohen

Keith P Klugman

Linda de Gouveia

Anne von Gottberg

Affiliations

Soon will be listed here.

Abstract

The emergence of multidrug-resistant (MDR) Streptococcus pneumoniae complicates disease management. We aimed to determine risk factors associated with MDR invasive pneumococcal disease (IPD) in South Africa and evaluate the potential for vaccination to reduce disease burden. IPD data collected by laboratory-based surveillance from 2003 through 2008 were analyzed. Multidrug resistance was defined as nonsusceptibility to any three or more different antibiotic classes. Risk factors for multidrug resistance were evaluated using multivariable logistic regression. Of 20,100 cases of IPD identified, 3,708 (18%) had MDR isolates, with the proportion increasing from 16% (461/2,891) to 20% (648/3,326) (P < 0.001) over the study period. Serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) accounted for 94% of MDR strains. Significant risk factors for MDR IPD included PCV13 (1,486/6,407; odds ratio [OR] of 6.3; 95% confidence interval [CI] of 5.0 to 7.9) and pediatric (3,382/9,980; OR of 12.8; 95% CI of 10.6 to 15.4) serotypes, age of <5 (802/3,110; OR of 2.0; 95% CI of 1.8 to 2.3) or ≥65 (39/239; OR of 1.5; 95% CI of 1.0 to 2.2) years versus age of 15 to 64 years, HIV infection (975/4,636; OR of 1.5; 95% CI of 1.2 to 1.8), previous antibiotic use (242/803; OR of 1.7; 95% CI of 1.4 to 2.1), previous hospital admissions (579/2,450; OR of 1.2; 95% CI of 1.03 to 1.4), urban location (883/4,375; OR of 2.0; 95% CI of 1.1 to 3.5), and tuberculosis treatment (246/1,021; OR of 1.2; 95% CI of 1.03 to 1.5). MDR IPD prevalence increased over the study period. The effect of many of the MDR risk factors could be reduced by more judicious use of antibiotics. Because PCV13 serotypes account for most MDR infections, pneumococcal vaccination may reduce the prevalence of multidrug resistance.

Citing Articles

Prevalence of ESBL-producing in adults with and without HIV presenting with urinary tract infections to primary care clinics in Zimbabwe.

Olaru I, Ferrand R, Chisenga M, Yeung S, Macrae B, Chonzi P JAC Antimicrob Resist. 2021; 3(2):dlab082.

PMID: 34223141 PMC: 8242135. DOI: 10.1093/jacamr/dlab082.

Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortality.

Kaufmann S Hum Vaccin Immunother. 2019; 15(11):2660-2665.

PMID: 30973039 PMC: 6930051. DOI: 10.1080/21645515.2019.1605817.

Burden of invasive pneumococcal disease among children in rural Mozambique: 2001-2012.

Sigauque B, Verani J, Massora S, Vubil D, Quinto L, Acacio S PLoS One. 2018; 13(1):e0190687.

PMID: 29304066 PMC: 5755904. DOI: 10.1371/journal.pone.0190687.

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015.

Lancet Infect Dis. 2017; 17(11):1133-1161.

PMID: 28843578 PMC: 5666185. DOI: 10.1016/S1473-3099(17)30396-1.

Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility.

Iroh Tam P, Thielen B, Obaro S, Brearley A, Kaizer A, Chu H Vaccine. 2017; 35(15):1817-1827.

PMID: 28284682 PMC: 5404696. DOI: 10.1016/j.vaccine.2017.02.045.

References

Sinha A, Levine O, Knoll M, Muhib F, Lieu T . Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet. 2007; 369(9559):389-96. DOI: 10.1016/S0140-6736(07)60195-0. View

Mera R, Miller L, Fritsche T, Jones R . Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008; 14(2):101-7. DOI: 10.1089/mdr.2008.0782. View

Goldstein F . Penicillin-resistant Streptococcus pneumoniae: selection by both beta-lactam and non-beta-lactam antibiotics. J Antimicrob Chemother. 1999; 44(2):141-4. DOI: 10.1093/jac/44.2.141. View

Catalan M, Fernandez J, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo De Quiros J . Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis. 1994; 18(5):766-9. DOI: 10.1093/clinids/18.5.766. View

Madhi S, Petersen K, Madhi A, Wasas A, Klugman K . Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J. 2001; 19(12):1141-7. DOI: 10.1097/00006454-200012000-00004. View

Buie K, Klugman K, von Gottberg A, Perovic O, Karstaedt A, Crewe-Brown H . Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. J Infect Dis. 2004; 189(11):1996-2000. DOI: 10.1086/386548. View

Schrag S, Pena C, Fernandez J, Sanchez J, Gomez V, Perez E . Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001; 286(1):49-56. DOI: 10.1001/jama.286.1.49. View

BULLEN B, HANSMAN D . Letter: Bacteraemia caused by tetracycline-resistant Pneumococcus type 1. Lancet. 1975; 1(7904):466-7. DOI: 10.1016/s0140-6736(75)91547-0. View

Doern G, Brueggemann A, Holley Jr H, Rauch A . Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996; 40(5):1208-13. PMC: 163293. DOI: 10.1128/AAC.40.5.1208. View

10.

Klugman K, Koornhof H . Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J Infect Dis. 1988; 158(5):956-64. DOI: 10.1093/infdis/158.5.956. View

11.

Miller E, Andrews N, Waight P, Slack M, George R . Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29(49):9127-31. DOI: 10.1016/j.vaccine.2011.09.112. View

12.

Andersson D . The biological cost of mutational antibiotic resistance: any practical conclusions?. Curr Opin Microbiol. 2006; 9(5):461-5. DOI: 10.1016/j.mib.2006.07.002. View

13.

Friedland I, Klugman K . Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet. 1992; 339(8790):405-8. DOI: 10.1016/0140-6736(92)90087-j. View

14.

Hsu H, Shutt K, Moore M, Beall B, Bennett N, Craig A . Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009; 360(3):244-56. PMC: 4663990. DOI: 10.1056/NEJMoa0800836. View

15.

Breiman R, Butler J, Tenover F, Elliott J, Facklam R . Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994; 271(23):1831-5. View

16.

French N, Gordon S, Mwalukomo T, White S, Mwafulirwa G, Longwe H . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362(9):812-22. PMC: 2873559. DOI: 10.1056/NEJMoa0903029. View

17.

Huebner RE , Wasas A, Klugman K . Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998. Int J Infect Dis. 2001; 4(4):214-8. DOI: 10.1016/s1201-9712(00)90112-7. View

18.

Appelbaum P, Bhamjee A, Scragg J, Hallett A, Bowen A, Cooper R . Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet. 1977; 2(8046):995-7. DOI: 10.1016/s0140-6736(77)92892-6. View

19.

Woolfson A, HUEBNER R, Wasas A, Chola S, Godfrey-Faussett P, Klugman K . Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bull World Health Organ. 1997; 75(5):453-62. PMC: 2487017. View

20.

Nunes M, von Gottberg A, de Gouveia L, Cohen C, Moore D, Klugman K . The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS. 2010; 25(4):453-62. DOI: 10.1097/QAD.0b013e328341b7f1. View